The German Digital Healthcare Act (DVG) at Seven Years: Review of the DiGA Ecosystem and its Impact on European Health Technology
- Nelson Advisors
- Feb 17
- 11 min read
The implementation of the Digital Healthcare Act (Digitale-Versorgung-Gesetz, DVG) on December 19, 2019, represents a seminal moment in the history of European health technology. By establishing the world’s first formal reimbursement pathway for digital health applications (Digitale Gesundheitsanwendungen, DiGA),
Germany effectively transformed software into a regulated medical intervention on par with traditional pharmaceuticals. Seven years on, the ecosystem has moved through distinct phases: an initial period of speculative fragmentation, a middle phase characterized by rapid market entry and clinical experimentation, and a current state of "industrial maturity" or "Regulatory Darwinism". This trajectory offers a profound case study in the complexities of integrating digital innovation into a conservative, highly regulated statutory health insurance (GKV) system that covers approximately 73 million lives.
The Strategic Genesis and Legislative Architecture of the DVG
The original intent of the DVG was to accelerate a digital transformation that had stagnated due to bureaucratic inertia and fragmented data silos within the German healthcare landscape. Legislators sought to improve patient autonomy, enhance the quality of care, and foster efficiency through "apps on prescription". The core mechanism for this was the amendment of the German Social Code (SGB V), particularly Section 139e, which authorized the Federal Institute for Drugs and Medical Devices (BfArM) to manage a central directory of reimbursable digital tools.
Legislation | Year | Primary Focus and Mechanism |
Digital Healthcare Act (DVG) | 2019 | Established the "Fast-Track" for DiGA and mandatory connection of pharmacies/hospitals to Telematics Infrastructure (TI). |
Digital Care and Nursing Act (DVPMG) | 2021 | Introduced Digital Nursing Applications (DiPA) and formalized digital identity frameworks. |
Digital Act (DigiG) | 2024 | Introduced the ePA opt-out model, expanded DiGA to Class IIb devices, and standardized e-prescriptions. |
DiGAV Amendment | 2026 | Mandated performance-based pricing (20% of fee) and "accompanying success measurement" (AbEM). |
The Fast-Track process was designed to reduce time-to-market by ensuring that BfArM would review a complete application within 90 days. This regulatory speed was unprecedented in European healthcare and acted as a major catalyst for healthtech investment. However, the initial focus on low-risk (Class I and IIa) devices limited the clinical scope of the early applications, a restriction that was only lifted by the 2024 Digital Act (DigiG) to include higher-risk Class IIb devices, thereby enabling the integration of complex interventions like remote monitoring.
Quantitative Evolution: Market Adoption and Utilisation Trends
The commercial success of the DVG can be measured through the lens of utilisation data and government expenditure. Between the fourth quarter of 2020 and the end of 2024, the program transitioned from a niche pilot into a quarter-billion-euro market segment.
Growth in Prescriptions and Expenditures
The cumulative expenditure for DiGA reached approximately €234 million by December 31, 2024. While this represents a mere fraction of the €316.2 billion annual GKV expenditure, the growth rate signals a profound shift in clinical acceptance. Utilisation increased by 85% between 2023 and 2024, moving from 225,000 activations to 423,000.
Time Period | Redeemed Prescriptions (Activations) | Estimated Expenditure |
Q4 2020 - Q3 2021 | ~41,000 | Minimal (Startup phase) |
Oct 2022 - Sep 2023 | ~209,000 | €113 million |
Jan 2024 - Dec 2024 | ~423,000 | €234 million (Cumulative) |
Cumulative (End 2024) | ~861,000 | €234 million |
Despite this growth, the average cost per activation has remained manageable at less than €271 (US$317), which industry analysts suggest is far below the cost of untreated chronic conditions and their associated complications. The market structure, however, remains heavily concentrated. The top 15 DiGAs account for 82% of all prescriptions, highlighting the importance of early market entry and robust physician referral networks.
Directory Dynamics: Approval vs. Attrition
As of the fourth quarter of 2024, the DiGA directory listed 59 therapeutic products, of which 38 had secured permanent listing and 21 remained provisionally listed. By early 2026, the total number of approved applications exceeded 75, though this figure is tempered by a significant attrition rate.
Approximately 20% of all applications that entered the directory have since been removed. This delisting occurs primarily because manufacturers fail to meet the rigorous clinical evidence standards required to move from provisional to permanent listing.
Status Category | Number of Applications (2025/2026) | Significance |
Permanently Reimbursable | 44 - 48 | Successfully proven positive healthcare effect (pVE). |
Provisionally Listed | 14 - 21 | Currently in the "trial year" for evidence development. |
Delisted (Failed Evidence) | 6 | Failed to provide significant proof of clinical benefit. |
Delisted (Commercial/Other) | 5 - 9 | Removed at manufacturer request or failed to complete trials. |
The attrition rate suggests that the Fast-Track is not a "free pass" to reimbursement but rather a "reimbursement with evidence development" phase that places the risk of clinical failure squarely on the manufacturer.
Clinical Evidence and the Proof of "Positive Healthcare Effect"
The central requirement for any DiGA is the demonstration of a "positive healthcare effect" (positiver Versorgungseffekt, pVE), which is evaluated based on either a "medical benefit" (mN) or "patient-relevant structural and procedural improvements" (pSVV). This dual-track evidence requirement was a major innovation of the DVG, recognising that digital tools can improve health not only through direct physiological intervention but also through behavioural changes, increased health literacy, and better adherence.
Medical Benefit vs. Procedural Improvements
Medical benefit (mN) is quantified through outcomes such as reduced pain, shortened disease duration, or improved quality of life. Procedural improvements (pSVV) focus on the patient's interaction with the healthcare system, including autonomy, coping with illness, and better coordination of care.
pVE Category | Outcome Examples | Required Proof |
Medical Benefit (mN) | Reduction in pain levels, improved sleep quality, lower HbA1c. | Comparative study (typically RCT) showing statistically significant improvement. |
Structural/Procedural (pSVV) | Improved adherence, health literacy, reduced burden on caregivers. | Validated questionnaires and real-world data reflecting system efficiency. |
Data from the German Clinical Trials Register (DRKS) shows a marked increase in the proportion of non-interventional studies (observational) since 2019, now exceeding 50% of all registrations. While BfArM accepts observational data for provisional listing, permanent reimbursement almost universally requires a randomised controlled trial (RCT) conducted within the German care context.
Insights from the DiGA Real Registry Study
The DiGAReal multicenter registry provides one of the few manufacturer-independent assessments of real-world effectiveness in specific patient populations, such as those with rheumatic diseases. The study followed 191 patients using applications for pain, depression, and weight management.
Application Area | Clinical Observation (DiGAReal Study) | Statistical Significance |
Insomnia (Somnio) | Significant improvement in sleep quality and fatigue. | $p = 0.006$ |
Back Pain (Kaia) | Significant reduction in pain and exhaustion. | $p = 0.05$ |
Weight Management | 50% to 82% of patients reported symptom improvement. | Mixed significance |
Patient Activation | No overall significant change in health literacy or activation scores. | Not Significant |
These results indicate that DiGAs are most successful when addressing targeted, episodic symptoms like sleep and acute pain, but they face a "glass ceiling" in significantly altering the long-term progression of chronic, systemic autoimmune conditions. Furthermore, while 81% of users found the apps easy to use, only 15% completed the full three-month program, suggesting that long-term adherence remains the "Achilles' heel" of digital therapeutics.
Economic Challenges: The Financial Paradox of Success
While the DVG was lauded as a catalyst for healthtech, the economic reality for many manufacturers has been harsh. The transition from venture-backed growth to sustainable reimbursement revenue has proven to be a fatal bottleneck for several high-profile startups.
The Price Negotiation Bottleneck
Under the original DVG rules, manufacturers set their own prices for the first 12 months of listing. The median price during this "innovation phase" was approximately €514. However, subsequent negotiations with the GKV-SV often resulted in a 50-60% price reduction, with the median permanent price settling around €221.
The "repayment clause" proved particularly damaging. If a final price was negotiated at €200 but the company had been charging €500 for the first year, they were often required to repay the difference to the health insurers retrospectively. For aidhere, the developer of the obesity app Zanadio, price negotiations dragged on for 18 months, resulting in an €8 million financial hole that led to insolvency despite having over 30,000 users.
Market Consolidation and Insolvency Trends
By 2025, the DiGA market entered a phase of consolidation. Investors shifted from funding "regulatory risk" (the hope of getting listed) to backing "regulatory moats" (firms with permanent listing and proven revenue). This shift led to several notable insolvencies and acquisitions by international strategic buyers.
Company | Status/Transaction | Strategic Context |
aidhere (Zanadio) | Insolvency / Acquired by Sidekick. | Victim of protracted GKV price negotiations. |
Cara Care | Acquired by Mahana Therapeutics. | Expansion of US-based DTx portfolios into Europe. |
mementor (Somnio) | Acquired by ResMed. | Strategic entry of US medical device giants into German DTx. |
Mika | Insolvency / Registry Removal. | Pivot to pharmaceutical partnerships due to insurer roadblocks. |
These failures highlight a structural flaw in the early DVG: it provided a "fast track" for regulatory entry but a "slow track" for financial stability. The "Dry Powder Paradox", where investors have capital but refuse to deploy it to struggling middle-tier firms, has further intensified this consolidation.
The 2026 Regulatory Pivot: Performance Based Pricing and AbEM
Recognising the rising costs and variable clinical outcomes, the German government implemented major amendments to the DiGAV and SGB V, effective January 2026. This shift represents the most significant evolution of the framework since 2019, moving the system toward a value-based care model.
Accompanying Success Measurement (AbEM)
Starting in 2026, manufacturers of permanently listed DiGAs must collect and provide "accompanying success measurement" data to BfArM. This requires ongoing, structured reporting on usage behavior and patient-reported outcomes.
Parameter | Measurement Requirement | Reporting Frequency |
Usage Patterns | Average duration, weekly frequency, and dropout rates. | Quarterly data generation. |
Patient Satisfaction | Survey-based data using DiGAV template questionnaires. | Bi-annual submission to BfArM. |
Patient Health Status | Longitudinal health outcome reporting. | First submission April 15, 2027. |
Critically, the 2026 rules mandate that at least 20% of the remuneration for each DiGA be tied to these performance-based factors. This "pay-for-performance" model is intended to address the skepticism of medical professionals and the financial concerns of the GKV-SV, ensuring that digital tools only consume health budgets when they deliver measurable value.
Expansion to Class IIb and AI Act Compliance
The DigiG of 2024 officially expanded the scope of DiGA to include risk class IIb medical devices. This change, fully operationalized by 2026, allows the framework to cover more complex therapeutic interventions such as tele-monitoring and advanced diagnostic algorithms. However, higher-risk devices are subject to even more stringent evidence criteria; unlike Class I or IIa devices, Class IIb manufacturers cannot rely purely on provisional listing and must prove a pVE prior to directory inclusion.
Additionally, the amended DiGAV now requires manufacturers to confirm compliance with the EU AI Act (Regulation 2024/1689) if their products utilise artificial intelligence. This "Regulatory Darwinism" effectively renders "black box" AI models un-investable, as the German clinical context now demands Article 13/14 compliance regarding transparency and human oversight.
International Proliferation: The "German Model" in Europe
The DVG has acted as a lighthouse for European digital health policy. France, the UK, and Belgium have all developed frameworks that draw heavily from the German experience, though with localised adaptations designed to avoid the "startup financing without return" trap seen in Germany.
Comparison with the French PECAN Model
In March 2023, France introduced the PECAN (Prise en Charge Anticipée Numérique) pathway, an early access scheme for digital medical devices (DMN).
Framework Feature | Germany (DiGA) | France (PECAN) |
Primary Stakeholder | BfArM (HTA) & GKV-SV (Price) | HAS (HTA) & CEPS (Price) |
Early Access Period | 12-24 Months | 12 Months (Strict) |
Product Scope | Software-only (DTx) | DTx and Tele-monitoring |
Risk Classes | I, IIa, IIb | I, IIa, IIb, III |
Pricing Method | Negotiated after evidence | Fixed lump sums (€435 - €780) |
The French model is notably stricter regarding timelines, requiring evidence submission within 6 to 9 months of entering the PECAN scheme, compared to the 12 to 24-month windows common in Germany. However, by including tele-monitoring and higher-risk (Class III) devices from the outset, France has positioned itself to capture a broader segment of the medtech market than Germany did in its first five years.
Fragmentation vs. Harmonisation
Despite these advancements, the European landscape remains fragmented. A 2025 analysis of HTA criteria for common DTx products like Deprexis (depression) and Velibra (anxiety) revealed that even when the same product is assessed by Germany, the UK, and France, the evidence requirements and comparators vary significantly. Only Germany and the UK are currently considered "highly mature" markets with dedicated, functional evaluation pathways and recent reimbursement history. Italy and Spain remain "hesitant," with no centralised pathways, resulting in high levels of regional inequality in patient access.
Physician Integration: The Persistent Adoption Gap
Perhaps the most significant challenge seven years post-DVG is not regulatory or clinical, but behavioral. While over 170,000 healthcare professionals in Germany are entitled to prescribe DiGAs, the actual adoption rate remains hindered by administrative and cultural barriers.
Barriers to Mainstream Prescription
Surveys of general practitioners (GPs), internal medicine physicians, and psychotherapists conducted between 2022 and 2025 identify a consistent set of hurdles.
Barrier Category | Specific Obstacle | Impact on Adoption |
Knowledge Gap | 87.6% of professionals report insufficient information. | Physicians are hesitant to recommend tools they don't fully understand. |
Workflow Friction | Prescription time ranges from 5 to 30 minutes. | Absence of an established prescribing routine inhibits adoption. |
Technical Barriers | Lack of interoperability with Practice Management Software (PVS). | Difficulty in retrieving data for clinical decision-making. |
Economic/Legal | 55.1% cite inadequate reimbursement for the effort of prescribing. | Concerns about liability and uncompensated administrative work. |
While 92% of internal medicine physicians believe DiGAs could improve care, only 31% have actually prescribed one. In psychiatry, where the evidence base is strongest, adoption is slightly higher, yet therapists express skepticism about the management of patients in crisis while using digital tools. The "lack of routine" remains the primary hindrance; unlike the automaticity of prescribing a drug, issuing a DiGA requires a conscious navigation of bureaucratic activation codes and patient onboarding that many doctors simply do not have the time to perform.
The Role of Telematics Infrastructure (TI)
The future of physician integration relies heavily on the success of the Telematics Infrastructure (TI) and the electronic patient record (ePA). The 2024 DigiG made the ePA mandatory for all statutory insured persons via an opt-out procedure, with implementation reaching a milestone in 2025. By integrating DiGA usage data directly into the e-prescription and medication summary, the system aims to reduce the "information silos" that currently make doctors wary of digital interventions.
Conclusion: A Success or a Stalled Revolution?
Seven years after the DVG's enactment, the answer to whether DiGA has been a success is multifaceted. For the European Healthtech Ecosystem, the DVG has been a triumph of market creation. It provided the first real playbook for digital therapeutic reimbursement, attracting billions in capital and encouraging established medtech and pharma giants to enter the space.
However, for SMEs and Early-Stage Startups, the framework has been a double-edged sword. The high costs of MDR compliance, clinical evidence generation, and the "punitive" nature of retrospective price negotiations have led to a market "shake-out" where only the most well-capitalized firms survive.
Area of Assessment | Verdict 7 Years On |
Patient Access | Success: 73 million people have access; nearly 1 million prescriptions issued. |
Investor Confidence | Mixed: Strong "Industrial Maturity" and M&A activity, but cautious "Regulatory Darwinism" for early rounds. |
Clinical Impact | Partial Success: Strong results in mental health and pain; "glass ceiling" in chronic systemic diseases. |
Systemic Integration | In Progress: Bottlenecks remain in physician routines and data interoperability. |
Looking toward 2026, the German model is shifting from "innovation support" to "performance accountability". The implementation of outcome-based pricing and the expansion into Class IIb devices signify a move toward a more disciplined era. If Germany can successfully bridge the adoption gap among physicians through better TI integration and robust success measurement, the DiGA framework will likely remain the definitive model for digital health global transformation. If not, it risks becoming a cautionary tale of a "digital inflation" where technological hype outpaced clinical and economic reality.
Nelson Advisors > European MedTech and HealthTech Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Comments